Development and Validation of a Nomogram for Patients Undergoing Transarterial Chemoembolization for Recurrent Hepatocellular Carcinoma After Hepatectomy
Diyang Xie,Zhongchen Li,Jia Yuan,Xin Yin,Rongxin Chen,Lan Zhang,Zhenggang Ren
DOI: https://doi.org/10.2147/jhc.s444682
2024-04-05
Journal of Hepatocellular Carcinoma
Abstract:Diyang Xie, Zhongchen Li, Jia Yuan, Xin Yin, Rongxin Chen, Lan Zhang, Zhenggang Ren Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Ministry of Education, Fudan University, Shanghai, 200032, People's Republic of China Correspondence: Zhenggang Ren, Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Ministry of Education, Fudan University, Shanghai, 200032, People's Republic of China, Tel/Fax +86-21-64037181, Email Purpose: This study aims to establish a prognostic nomogram for patients who underwent transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after hepatectomy. Patients and Methods: Patients who underwent TACE for recurrent early- and middle-stage HCC after hepatectomy between 2009.01 and 2015.12 were included. Enrolled patients were randomly divided into training (n=345) and validation (n=173) cohorts according to a computer-generated randomized number. Independent factors for overall survival (OS) were determined and included in the nomogram based on the univariate and multivariate analyses of the training group. The nomogram was validated and compared to other prognostic models. Discriminative ability and predictive accuracy were determined using the Harrell C index (C-index), area under the receiver operating characteristic curve (AUROC), and calibration curve. Results: The final nomogram was established based on four parameters including resection-to-TACE time interval, recurrent tumor diameter, recurrent tumor number, and AFP level. The C-indexes of the nomogram for predicting OS were 0.67 (95% CI 0.63– 0.70) and 0.71 (95% CI 0.68– 0.74) in the training and validation cohort respectively. The AUROCs for predicting the 1-year, 2-year and 3-year OS based on the nomogram were also superior to those of the other models. The calibration curve for 3-year survival showed a high congruence between the predicted and actual survival probabilities. According to the scores calculated by the nomogram, patients were stratified into three subgroups: high-risk (scoring ≥ 53 points), middle-risk (scoring ≥ 26 and < 53 points), and low-risk (scoring < 26 points) subgroups with a median OS of 10.1 (95% CI 0.63– 0.70), 20.3 (95% CI 17.5– 22.5) and 47.0 (95% CI 34.2– 59.8) months, respectively. Conclusion: The proposed nomogram served as a new tool to predict individual survival in patients who underwent TACE for recurrent HCC after hepatectomy, with favorable performance and discrimination. For high-risk patients, treatment should be optimized beyond TACE alone based on the nomogram. Keywords: hepatocellular carcinoma, transarterial chemoembolization, nomogram Liver cancer is the sixth most prevalent and the third most lethal malignancy worldwide. 1 Approximately 410 thousand patients were newly diagnosed with liver cancer in China in 2020 ( https://gco.iarc.fr ), accounting for 45.3% of new global new cases. 2 Hepatocellular carcinoma (HCC) constitutes the majority of primary liver cancers, accounting for 85–90% of cases. Most HCC cases in China have a background of chronic hepatitis derived from hepatitis B virus (HBV) infection and are characterized by high invasiveness and poor differentiation. 3,4 According to a previous report, only 36% of HCC cases were initially diagnosed at an early stage and qualified for radical treatment. 5 Hepatectomy remains the mainstay radical treatment. However, recurrence occurred to 70% of patients within 5 years after hepatectomy. Consistent with the treatment algorithm for newly diagnosed HCC patients, transarterial chemoembolization (TACE) is also indicated for patients with recurrent HCC after hepatectomy at an intermediate stage or at an early stage inappropriate for a second resection owing to tumor size, location, or complicated diseases. 6 The prognosis of patients receiving TACE varies widely, depending on the heterogeneity of the target population. According to previous studies, the median overall survival (OS) for newly-diagnosed patients who underwent TACE for HCC varied from 13 to 43 months. 7 Therefore, various stratification tools have been established to predict the long-term prognosis for patients after TACE, including the up-to-seven, 8 four-and-seven, 9 hepatoma arterial embolization prognostic (HAP), 10 modified HAP (mHAP), 11 mHAP-II 12 and six-and-twelve 13 scoring systems. Whether these systems based mostly on the data of treatment-naïve patients are also applicable for patients with recurrent HCC is unclear. Currently, there has been no established prognostic systems for patients who received TACE for recurrent HCC after hepatectomy. Breakthroughs in syste -Abstract Truncated-
oncology